New cocktail aims to tackle tough lymphoma

NCT ID NCT06854003

Recruiting now Disease control Sponsor: Christine Ryan Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a five-drug combination for people with untreated mantle cell lymphoma. The treatment includes standard chemotherapy plus newer targeted drugs. After initial therapy, some participants will receive an additional drug (sonrotoclax) to see if it helps keep the cancer away longer. The study will enroll about 60 people and track how well the cancer responds and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bendamustine, rituximab, cytarabine, zanubrutinib, and sonrotoclax
What this could lead to: If successful, this could offer a more effective first-line treatment for mantle cell lymphoma, potentially leading to longer remissions and better disease control.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results are preliminary. The drug combination may cause serious side effects, and it's unknown if adding sonrotoclax will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA MANTLE CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Email: •••••@•••••
Mayo Clinic
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Mayo Clinic Arizona
NOT_YET_RECRUITING

Phoenix, Arizona, 85054, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.